MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) released its quarterly earnings data on Monday. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by $0.78, Bloomberg Earnings reports.

MabVax Therapeutics Holdings (NASDAQ MBVX) traded down 4.6229% during trading on Wednesday, hitting $0.4869. 72,618 shares of the stock were exchanged. The stock has a 50 day moving average of $0.95 and a 200-day moving average of $1.90. The stock’s market cap is $4.24 million. MabVax Therapeutics Holdings has a 52 week low of $0.49 and a 52 week high of $6.05.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at

MabVax Therapeutics Holdings Company Profile

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.